The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
April 22nd 2024
Investigators found that younger age groups had significantly longer lengths of stay compared to those older than 75 years.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Pneumococcal Vaccine Candidate Shows Promise in Adults Aged 65 Years and Older
April 20th 2023VAX-24 is designed to prevent invasive pneumococcal disease and pneumonia, which can be most serious for infants, young children, older adults, and those with immune deficiencies or some chronic health conditions.
Read More
FDA Approves Rezafungin Injection for the Treatment of Candidemia, Invasive Candidiasis
March 24th 2023Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.
Read More
Study Shows PCV13 Followed by PPSV23 Protects Against Pneumococcal Diseases in Patients With SCD
March 6th 2023The immunological efficacy of the 13-valent conjugate pneumococcal vaccine followed by 23-valent polysaccharide vaccine has been poorly documented in adult patients with sickle cell disease.
Read More